The current financial score of Standard BioTools Inc is 6.88. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 20.10M, representing a year-over-year decrease of 7.62%, while its net profit experienced a year-over-year decrease of 20.03%.
The current valuation score of Standard BioTools Inc is 9.75. Its current P/E ratio is 3.65, which is 73.97% below the recent high of 6.35 and 263.24% above the recent low of -5.96.
The current earnings forecast score of Standard BioTools Inc is 8.00. The average price target is 1.55, with a high of 1.75 and a low of 1.35.
The current price momentum score of Standard BioTools Inc is 4.39. Currently, the stock price is trading between the resistance level at 0.78 and the support level at 0.65, making it suitable for range-bound swing trading.
The current institutional shareholding score of Standard BioTools Inc is 7.00. The latest institutional shareholding proportion is 81.30%, representing a quarter-over-quarter increase of 5.13%. The largest institutional shareholder is Chuck Royce, holding a total of 4.53M shares, representing 0.03% of shares outstanding, with 28.02% increase in holdings.
The current risk assessment score of Standard BioTools Inc is 3.67. The company's beta value is 1.37. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.